General Cancer
Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd
During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
Relacorilant Extends Survival in Platinum-Resistant Ovarian Cancer
The combination of relacorilant and nab-paclitaxel improved progression-free and overall survival in patients with platinum-resistant ovarian cancer.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
CAN-2409 Shows Strong OS Outcomes in ICI-Refractory NSCLC
Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC.
FDA Grants Approval to Durvalumab in MIBC
This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.
